# Phase 1 Safety Study of ALRN-5281 in Healthy Subjects

> **NCT01775358** · PHASE1 · COMPLETED · sponsor: **Aileron Therapeutics, Inc.** · enrollment: 33 (actual)

## Conditions studied

- Growth Hormone Deficiency

## Interventions

- **DRUG:** ALRN-5281 0.015 mg/kg
- **DRUG:** ALRN-5281 0.05 mg/kg
- **DRUG:** ALRN-5281 0.15 mg/kg
- **DRUG:** Placebo 0.015 mg/kg
- **DRUG:** Placebo 0.05mg/kg
- **DRUG:** Placebo 0.15mg/kg

## Key facts

- **NCT ID:** NCT01775358
- **Lead sponsor:** Aileron Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2013-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01775358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01775358, "Phase 1 Safety Study of ALRN-5281 in Healthy Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01775358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*